Form 4: Alkermes CFO Iain Michael Brown Reports Stock Transactions

Iain Michael Brown, CFO of Alkermes plc, reports the acquisition and disposal of ordinary shares and derivative securities.

Summary

• Iain Michael Brown, the SVP and Chief Financial Officer of Alkermes plc, filed a Form 4 detailing changes in beneficial ownership.
• On February 23, 2024, Brown acquired 5,825 ordinary shares through the vesting of restricted stock units.
• Also on February 23, 2024, Brown disposed of 2,587 ordinary shares at a price of $29.57.
• Following these transactions, Brown beneficially owns 116,344 ordinary shares.
• On February 26, 2024, Brown was granted an option to buy 90,971 ordinary shares at $30.04, exercisable in installments starting February 26, 2025, and expiring on February 26, 2034.
• On February 26, 2024, Brown was granted 22,471 restricted stock units, vesting in installments starting February 26, 2025.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the document primarily reports routine transactions. The disposal of shares is offset by the granting of new options and restricted stock units.

Positives

• The vesting of restricted stock units and granting of stock options and restricted stock units to the CFO could be seen as an incentive to align his interests with those of the shareholders.

Negatives

• The disposal of 2,587 shares by the CFO could be interpreted negatively, although it may be related to tax obligations from the vesting of restricted stock units.

Risks

• There are no specific risks mentioned in this document, but insider transactions always carry the risk of being misinterpreted by the market.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. These filings are closely watched by investors for signals about management's confidence in the company's prospects.

Comparison to Industry Standards

• Stock option and restricted stock unit grants are a common form of executive compensation in the pharmaceutical industry, used to align management incentives with shareholder value.
• The vesting schedules and exercise prices are typical for such grants, often vesting over a four-year period.
• Comparable companies such as Biogen, Vertex Pharmaceuticals, and Incyte also utilize similar equity-based compensation plans for their executives.

Stakeholder Impact

• The transactions reported in this filing may influence investor sentiment regarding Alkermes plc.
• The equity-based compensation impacts the CFO's alignment with shareholder interests.

Key Dates